transcription factor like 5Genealiases: CHA · E2BP-1 · Figlb · SOSF1 · bHLHe82
Q-omics provides the consensus-scored TCFL5 profile across patient tissues and cancer cell-line models. TCFL5 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, TCFL5 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, TCFL5 RNA expression shows 18,945 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, HNSC, and UVM as cancer lineages where TCFL5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TCFL5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TCFL5 survival associations across molecular data types. TCFL5 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TCFL5 RNA expression–survival associations across cancer types. High TCFL5 expression shows unfavorable associations in BLCA, KIRP, LIHC, UCEC, HNSC and LGG. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify BLCA as the clearest survival context for TCFL5 RNA expression.
This table summarizes TCFL5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TCFL5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TCFL5 shows lower tumor expression in KIRC and THCA and higher tumor expression in HNSC, COAD, LIHC and LUAD. The HNSC box plot shows higher TCFL5 RNA expression in tumor versus normal tissue (log2 FC = +1.259, t-test p < 0.001).
This table shows molecular features associated with TCFL5 in patient tissues and cancer cell lines. In patient samples, TCFL5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TCFL5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
